Associate Professor, Medicine, Tufts Medical Center
Infectious Disease
Dr. Helen W. Boucher, MD
|
|
Give Review
Helen Boucher practices Infectious Disease. She graduated from University of Texas Medical School. She over the years received 2 awards: "Boston Magazine" and "CMS Meaningful Use Stage 1 Certification". Dr. Helen W. Boucher is a published doctor. She has 48 papers published. The most current publication "A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative..." She is registered with Medicare.
Publications
- Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
- Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to 'get smart'.
- Reply to DiNubile.
- A tribute to dr robert C. Moellering jr (1937-2014).
- The Department of Defense Fights the battle against Antimicrobial Resistance: Can the US win the war?
- Imminent Challenges: Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancy.
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America.
- Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
- Early High-Dose Daptomycin for MRSA Bloodstream Infections with Elevated Vanomcycin MICs: Ready for Prime Time?
- Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: u...
- First report of a left ventricular assist device infection caused by Staphylococcus schleiferi subspecies coagulans: a coagulase-positive organism.
- Daptomycin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infection and Elevated Vancomycin Minimum Inhibitory Concentrations: Has the Time Come?
- Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.
- Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication.
- Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
- Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
- Is it possible to blind a trial for community-acquired pneumonia?
- Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.
- Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
- Epidemiology of methicillin-resistant Staphylococcus aureus.
- Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
- Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
- Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
- To treat or not to treat: adjunctive antibiotics for uncomplicated abscesses.
- Rifampin-containing regimens for community-associated skin infection: a hazard without known benefit.
- A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative...
- Design and analysis of group sequential logrank tests in maximum duration versus information trials.
- Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals.
- Daptomycin compared to standard therapy for the treatment of native valve endocarditis.
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with meth...
- Serious infections caused by methicillin-resistant Staphylococcus aureus.
- In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
- In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
- Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia.
- Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.
- Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
- Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and va...
- Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.
- Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.
- Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the rando...
- Combating antimicrobial resistance: policy recommendations to save lives.
- Gram-negative bloodstream infections.
- The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
- Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
- Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
- Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of othe...
- New agents for Staphylococcus aureus endocarditis.
Schools
University of Texas At Houston Medical School At Houston
New England Deaconess Hospital
Beth Israel Deaconess Med Center
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Boston Magazine
- CMS Meaningful Use Stage 1 Certification
Education
-
Beth Israel Deaconess Medical Center -
University of Texas Medical School
Hospital
-
Tufts Medical Center
Drug Facts
| NPI NUMBER | 1821024589 | |
| NPPES Provider LastName | BOUCHER | |
| NPPES Provider FirstName | HELEN | |
| NPPES Provider ZIPCode | 021111526 | |
| NPPES Provider State | MA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 315.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821024589 |
| Last Name Of The Provider | BOUCHER |
| First Name Of The Provider | HELEN |
| View All |
Similar Doctors
|
|
Dr. Roby P. Bhattacharyya, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ingrid V. Bassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dylan B. Tierney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roger L. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian Wood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul E. Sax, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lisa M. Bebell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge L. Barinaga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Davidson H. Hamer, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Eavan Muldoon
This Doctor is OpenDoctor Recommended.
|